Board of Directors

The Board of Directors of Medicure Inc. is responsible for the stewardship of the Company and for supervising the management of the business and affairs of the Company, in accordance with applicable law, the Company's Bylaws and applicable rules and regulations of the Toronto Stock Exchange. The Board is elected by the shareholders and represents all shareholders' interests in creating shareholder value.

Albert D. Friesen, PhD., O.M., C.M.

President, Chief Executive Officer & Chairman of the Board

Albert D. Friesen is a founder and has served as CEO and Chair of Medicure Inc. since 1997. He is also a founder of Genesys Venture Inc. (GVI), and current serves as President. Dr. Friesen has been instrumental in the founding and development of several health industry companies, including ABI Biotechnology (now Apotex Fermentation), Canada's first profitable biotech company, and the Winnipeg Rh Institute, where he led the development of Canada's first biotech product, WinRho. Dr. Friesen has also played a key role in a number of regional and national organizations, including a founder and first Board of Director Chair of the Industrial Biotechnology Association of Canada (now BIOTECanada). Dr. Friesen received his Ph.D. in protein chemistry from the University of Manitoba.

Arnold Naimark, M.D.

Director

Arnold Naimark, O.C., O.M., M.D., L.L.D., F.R.C.P.(C), F.R.S.C, FCAHS is President Emeritus and Dean of Medicine Emeritus and Professor of Medicine and Physiology at the University of Manitoba. He is currently Director of the Centre for the Advancement of Medicine, Chair of Genome Prairie and Chair of CancerCare Manitoba. Dr. Naimark also serves on the Research Council of the Canadian Institute for Advanced Research, the National Statistics Council of Canada and is Vice-Chair of the Statistics Canada Audit Committee.

Previously, Dr. Naimark has served as Chair of Health Canada's Ministerial Science Advisory Board, Member of the International Advisory Committee on Research of the Alberta Cancer Board, Research Institute, Vice-Chair of the Manitoba Health Research Council and Director of the Robarts Research Institute. He is the founding Chairman of the North Portage Development Corporation, the Canadian Health Services Research Foundation and the Canadian Biotechnology Advisory Committee. He has served as President of several academic bodies including, the Canadian Physiological Society, the Canadian Society for Clinical Investigation, the Association of Canadian Medical Colleges, the Association of Universities and Colleges of Canada and as Chairman of the Association of Commonwealth Universities. Dr. Naimark is an Officer of the Order of Canada, a Member of the Order of Manitoba and a Fellow of the Royal College of Physicians and Surgeons of Canada, the Royal Society of Canada, and the Canadian Academy of Health Sciences.

Kerrie Hayes

Director

Ms. Hayes is Director, Research Contracts at the University of Manitoba. In this role she provides institutional oversight for complex research contracts and international partnership contracting. Previously, Ms. Hayes was Director of Business Development at Medicure and has experience as an intellectual property manager with a life sciences incubator. She holds an M.Sc. in Biosciences from the University of Winnipeg.

Brent Fawkes, CA

Director

Brent Fawkes is a Chartered Accountant with over 20 years of experience in accounting and finance. Mr. Fawkes is currently the Vice President of Finance with Standard Aero Limited, one of the world's largest independent providers of a variety of aerospace services serving a diverse array of customers in business and general aviation, airline, military, helicopter, components, energy and VIP completions markets. In his current role, Mr. Fawkes is responsible for the oversight of the finance department including external reporting, budgeting and planning and treasury management.

James Kinley, CA

Director

James Kinley is a Chartered Professional Accountant ("CPA, CA") and is currently the Chief Financial Officer of a publicly traded, clinical stage drug development company, Algernon Pharmaceuticals Inc. (CSE: AGN). Mr. Kinley has over 15 years of experience in building, leading, and advising corporations through their daily operations as well as on complex restructurings, mergers, acquisitions, and capital markets transactions, including structuring and negotiating favorable terms with commercial and investment banks. Mr. Kinley was previously the Chief Financial Officer of Medicure Inc. for approximately ten years from 2011 to 2021.

Unite Interactive